Patients receiving SOR102 twice daily (BID) showed notable improvements over 6 weeks:
:
Currently, many advanced therapies for UC require intravenous (IV) infusions or subcutaneous injections, which can be inconvenient and lead to systemic immunosuppression (side effects throughout the whole body). SOR102 offers several advantages: sor102